Clinical Trial: NCT02166463
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 3| Lead Sponsor: | National Cancer Institute (NCI) |
| Information Provided By: | National Cancer Institute (NCI) |
| Last Update Posted: | 2026-10-01 |
Study Overview
Brief Summary
This phase III trial studies brentuximab vedotin and combination chemotherapy to see how well they work compared to combination chemotherapy alone in treating children and young adults with stage IIB with bulk, stage IIIB, IVA, or IVB Hodgkin lymphoma. Combinations of biological substances in brentuximab vedotin may be able to carry cancer-killing substances directly to Hodgkin lymphoma cells. Chemotherapy drugs, such as doxorubicin hydrochloride, bleomycin sulfate, vincristine sulfate, etoposide, prednisone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known if combination chemotherapy is more effective with or without brentuximab vedotin in treating children with high-risk Hodgkin lymphoma.
Official Title
Conditions
Intervention / Treatment
- Biological: Bleomycin Sulfate
- Drug: Brentuximab Vedotin
- Drug: Cyclophosphamide
- Drug: Doxorubicin Hydrochloride
- Drug: Etoposide
- Other: Laboratory Biomarker Analysis
- Drug: Methylprednisolone
- Other: Pharmacological Study
- Drug: Prednisone
- Other: Quality-of-Life Assessment
- Other: Questionnaire Administration
- Drug: Vincristine Sulfate
Other Study ID Numbers
- NCI-2014-01223
- NCI-2014-01223
- s15-00950
- AHOD1331
- AHOD1331
- U10CA180886
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | National Cancer Institute (NCI) |
| Information Provided By: | National Cancer Institute (NCI) |
| Last Update Posted: | 2026-10-01 |
Study Overview
Brief Summary
This phase III trial studies brentuximab vedotin and combination chemotherapy to see how well they work compared to combination chemotherapy alone in treating children and young adults with stage IIB with bulk, stage IIIB, IVA, or IVB Hodgkin lymphoma. Combinations of biological substances in brentuximab vedotin may be able to carry cancer-killing substances directly to Hodgkin lymphoma cells. Chemotherapy drugs, such as doxorubicin hydrochloride, bleomycin sulfate, vincristine sulfate, etoposide, prednisone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known if combination chemotherapy is more effective with or without brentuximab vedotin in treating children with high-risk Hodgkin lymphoma.
Official Title
Conditions
Intervention / Treatment
- Biological: Bleomycin Sulfate
- Drug: Brentuximab Vedotin
- Drug: Cyclophosphamide
- Drug: Doxorubicin Hydrochloride
- Drug: Etoposide
- Other: Laboratory Biomarker Analysis
- Drug: Methylprednisolone
- Other: Pharmacological Study
- Drug: Prednisone
- Other: Quality-of-Life Assessment
- Other: Questionnaire Administration
- Drug: Vincristine Sulfate
Other Study ID Numbers
- NCI-2014-01223
- NCI-2014-01223
- s15-00950
- AHOD1331
- AHOD1331
- U10CA180886